Pracinostat (BioDeep_00000855551)
代谢物信息卡片
化学式: C20H30N4O2 (358.23686399999997)
中文名称: (2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO
InChI: InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
描述信息
C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:95071
- PubChem: 49855250
- DrugBank: DB05223
- ChEMBL: CHEMBL1851943
- CAS: 929016-96-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Yasmin M Abaza, Tapan M Kadia, Elias J Jabbour, Marina Y Konopleva, Gautam Borthakur, Alessandra Ferrajoli, Zeev Estrov, William G Wierda, Ana Alfonso, Toh Han Chong, Charles Chuah, Liang-Piu Koh, Boon-Cher Goh, Julie E Chang, Daniel E Durkes, Maria Cielo Foudray, Hagop M Kantarjian, Xiao Qin Dong, Guillermo Garcia-Manero. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Cancer.
2017 Dec; 123(24):4851-4859. doi:
10.1002/cncr.30949
. [PMID: 28841236] - Paul Hermant, Damien Bosc, Catherine Piveteau, Ronan Gealageas, BaoVy Lam, Cyril Ronco, Matthieu Roignant, Hasina Tolojanahary, Ludovic Jean, Pierre-Yves Renard, Mohamed Lemdani, Marilyne Bourotte, Adrien Herledan, Corentin Bedart, Alexandre Biela, Florence Leroux, Benoit Deprez, Rebecca Deprez-Poulain. Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.
Journal of medicinal chemistry.
2017 11; 60(21):9067-9089. doi:
10.1021/acs.jmedchem.7b01444
. [PMID: 28985084] - Sun-Woo Kang, Soung-Min Lee, Joo-Yong Kim, So-Yeon Kim, Yeong-Hoon Kim, Tae-Hee Kim, Mi-Seon Kang, Won-Hee Jang, Su-Kil Seo. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
International immunopharmacology.
2017 Jan; 42(?):25-31. doi:
10.1016/j.intimp.2016.11.008
. [PMID: 27855304] - Shabir Ahmad Ganai. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Pharmaceutical biology.
2016 Sep; 54(9):1926-35. doi:
10.3109/13880209.2015.1135966
. [PMID: 26853619] - Ramesh Jayaraman, Venkatesh Pilla Reddy, Mohammed Khalid Pasha, Haishan Wang, Kanda Sangthongpitag, Pauline Yeo, Chang Yong Hu, Xiaofeng Wu, Liu Xin, Evelyn Goh, Lee Sun New, Kantharaj Ethirajulu. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Dec; 39(12):2219-32. doi:
10.1124/dmd.111.041558
. [PMID: 21873472] - W P Yong, B C Goh, R A Soo, H C Toh, K Ethirajulu, J Wood, V Novotny-Diermayr, S C Lee, W L Yeo, D Chan, D Lim, E Seah, R Lim, J Zhu. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2011 Nov; 22(11):2516-2522. doi:
10.1093/annonc/mdq784
. [PMID: 21385886] - Veronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, Mohammed Khalid Pasha, Ramesh Jayaraman, Hannes Hentze, Wei-Peng Yong, Boon-Cher Goh, Han-Chong Toh, Kantharaj Ethirajulu, Joy Zhu, Jeanette Marjorie Wood. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.
Molecular cancer therapeutics.
2011 Jul; 10(7):1207-17. doi:
10.1158/1535-7163.mct-11-0044
. [PMID: 21586629]